Using real‐world evidence for pharmacovigilance and drug safety‐related decision making by a resource‐limited health authority: 10 years of experience in Taiwan

Abstract

Purpose: Real-world evidence has become increasingly relevant in regulatory decision making. Compared to large regulatory bodies, the national pharmacovigilance system in Taiwan is still under development, and the aim of this study is to demonstrate how a resource-limited health authority utilizes real-world evidence in decision making. Methods: We described different sources of real-world data available in Taiwan and illustrated the structural framework that integrates real-world evidence into Taiwan's national pharmacovigilance system. Additionally, we reviewed real-world studies conducted in the past 10 years and provided examples to show how these studies influenced drug safety-related decision making in Taiwan. Results: During the past 10 years, real-world evidence used when making drug safety-related regulatory decisions in Taiwan was mainly generated from nationwide claims databases, but other sources of real-world data, such as national registries and large electronic hospital databases, also became available recently. Different types of real-world evidence, including drug utilization studies, risk evaluation studies, and risk minimization measure evaluation studies, have been used to support regulatory decisions in Taiwan. Conclusions: Through collaborations between the government and academics, Taiwan has started to integrate real-world evidence into the national pharmacovigilance system. However, future efforts, including linkages between different sources of real-world data and improvements in procedural and methodological practices, are needed to generate more regulatory-quality real-world evidence.

Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward

“…How this will be done has not been clearly stated by the regulatory authorities in United States or Taiwan. Thus far, Taiwan had successfully used real world evidence to inform regulatory decisions on the approval of pharmaceuticals, i.e., sapropterin tablet, oral ketoconazole, and alteplase ( Chen et al, 2020 ). Therefore, such experience might prove useful in addition to experience sharing and learning from other jurisdictions who have considered or may be considering the use of real world evidence ( Earl, 2019 ; Takashima et al, 2021 ).…”

A New Drug Safety Signal Detection and Triage System Integrating Sequence Symmetry Analysis and Tree-Based Scan Statistics with Longitudinal Data

“…In addition to the existing SRS which has been seen as the cornerstone of drug safety surveillance, we proposed a triage algorithm utilizing longitudinal data for active surveillance. We incorporated guidance from the Council for International Organizations of Medical Sciences (CIOMS) Working Group VIII 20 and the current structural framework used in Taiwan’s national pharmacovigilance system 21 to construct the new system, with integrated data-mining approaches to aid in signal generation and with a classification algorithm to categorize and prioritize safety signals.…”